世卫组织暂停了对羟氯喹的研究

The World Health Organization is pausing the use of hydroxychloroquine in its global study of COVID-19 treatments amid a review of safety data, officials announced Monday.

周一，世界卫生组织官员宣布，审查安全数据期间，在对新冠病毒疗法的全球研究中暂停使用羟氯喹。

The move follows findings from a large observational study, published Friday, that found increased risk of heart problems and death in COVID-19 patients who used chloroquine and hydroxychloroquine.

此前，在周五发表的一项大型观察性研究中发现，使用氯喹和羟氯喹的新冠病人患心脏病和死亡的风险会增加，因此做出这一决定。

It's a scientific decision nonetheless fraught¹ with politics: U.S. President Donald Trump² is a champion of hydroxychloroquine, revealing last week that he's taking it to prevent COVID-19. He has threatened to cut off U.S. funding to the WHO within a month absent unspecified reforms.

尽管如此，但这一科学决定充满政治因素：美国总统唐纳德·特朗普支持羟氯喹，他上周说正在吃羟氯喹来预防感染新冠病毒。他威胁说，如果不进行具体改革，将在一个月内切断美国对世界卫生组织的资金支持。

The executive committee of the WHO's Solidarity³ trial met last Saturday, said WHO Chief Scientist Soumya Swaminathan, and decided⁴ "in the light of this uncertainty⁵ that we should be proactive, err⁶ on the side of caution and suspend enrollment⁷ temporarily into the hydroxychloroquine arm." (Chloroquine is not part of the trial.)

世界卫生组织首席科学家Soumya Swaminathan说，世界卫生组织的SOLIDARITY临床试验执行委员会上周召开会议，决定“鉴于这种不确定性，我们要有前瞻性，谨慎行事，暂停使用羟氯喹”。（氯喹并不是此次试验用药。）

The meeting came a day after the Lancet published the largest observational study of the malaria⁸ drugs to date, and as some national regulators began expressing concern about using the drug.

会议召开前一天，《柳叶刀》发表了迄今针对疟疾药物最大的观察性研究，一些国家监管机构开始表现出对使用这种药物的担忧。

WHO officials estimated the pause would last a week or two as the trial's data safety monitoring board considers information already collected from the Solidarity trial and other ongoing⁹ studies to determine whether it's safe to continue with hydroxychloroquine.

世界卫生组织官员估计暂停会持续一至两周，因为试验数据安全监测委员会要参考从SOLIDARITY临床试验和其他进行中的研究中所收集的信息，从而确定继续使用羟氯喹是否安全。

The study, a randomized trial, has enrolled¹⁰ 3,500 patients in at least 17 countries since March to study four medicines, including hydroxychloroquine.

这项研究是随机试验，从三月份开始在至少17个国家召集了3,500名患者来研究4种药物，其中就包括羟氯喹。

 

分享到：